531752 — Biogen Pharmachem Industries Income Statement
0.000.00%
Last trade - 00:00
- IN₹743.97m
- IN₹798.78m
- 21
- 28
- 66
- 28
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.5 | 0 | 16.2 | 24.7 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.399 | 0 | 1.42 | 4.59 | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.53 | 1.17 | 32.3 | 24.9 | 4.57 |
Operating Profit | -0.035 | -1.17 | -16 | -0.154 | -4.57 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.035 | -1.17 | -16 | -0.086 | 4.55 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.035 | -1.17 | -16 | -0.086 | 4.55 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.035 | -1.17 | -16 | -0.086 | 4.55 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.035 | -1.17 | -16 | -0.086 | 4.55 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0 | -0.002 | -0.025 | -0 | 0.007 |